Evaluation of radiomics as a predictor of efficacy and the tumor immune microenvironment in anti‐<scp>PD</scp>‐1 <scp>mAb</scp> treated recurrent/metastatic squamous cell carcinoma of the head and neck patientsDan P. Zandberg, Rivka R. Colen, Murat Ak et al.|Head & Neck|2024Cited by 5